All posts by admin

Fabre-Kramer Pharmaceuticals, Inc. > Articles by: admin

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

September 28, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

January 27, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets

January 5, 2023 admin Press Releases No comments yet

Fabre-Kramer Partners with Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo™ (Gepirone ER) Tablets